Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Cancer Research|February 1, 1992
Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation schemeM A Graham, D R Newell, B J Foster, et al.
Biochimie|January 1, 1995
The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapyR J Griffin, N J Curtin, D R Newell, et al.
Advances in Enzyme Regulation|January 1, 1989
Thymidylate synthase: a target for anticancer drug designK R Harrap, A L Jackman, D R Newell, et al.
Seminars in Oncology|April 1, 1991
The pharmacokinetics of oral lonidamine in breast and lung cancer patientsD R Newell, J Mansi, J Hardy, et al.
British Journal of Cancer|January 1, 1997
Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapyB Peng, M J Tilby, M W English, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levelsS Ghazal-Aswad, M J Tilby, M Lind, et al.
British Journal of Cancer|December 17, 2009
Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cellsN Johnson, J Bentley, L-Z Wang, et al.
Anticancer Research|November 1, 1994
The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a reviewP Bin, A V Boddy, M W English, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitroE Marshman, D R Newell, A H Calvert, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)D L Alison, D R Newell, C Sessa, et al.
Pageof 12